A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA-CER).

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA-CER).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Vorapaxar (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TRA-CER; TRACER
  • Sponsors Merck & Co
  • Most Recent Events

    • 30 Aug 2017 Results (n=6146) assessing genetic variability, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
    • 10 Jun 2017 Biomarkers information updated
    • 14 Mar 2017 Results of prognostic impact of myocardial infarction and bleeding during extended follow-up published in the European Heart Journal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top